[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 51 of about 51
1. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, Meijer CJ, Willemze R: Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood; 2000 Jun 15;95(12):3653-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
  • To evaluate our diagnostic and therapeutic guidelines, clinical and long-term follow-up data of 219 patients with primary or secondary cutaneous CD30(+) lymphoproliferative disorders were evaluated.
  • The study group included 118 patients with lymphomatoid papulosis (LyP; group 1), 79 patients with primary cutaneous CD30(+) large T-cell lymphoma (LTCL; group 2), 11 patients with CD30(+) LTCL and skin and regional lymph node involvement (group 3), and 11 patients with secondary cutaneous CD30(+) LTCL (group 4).
  • Patients with LyP often did not receive any specific treatment, whereas most patients with primary cutaneous CD30(+) LTCL were treated with radiotherapy or excision.
  • All patients with skin-limited disease from groups 1 and 2 who were treated with multiagent chemotherapy had 1 or more skin relapses.
  • The calculated risk for systemic disease within 10 years of diagnosis was 4% for group 1, 16% for group 2, and 20% for group 3 (after initial therapy).
  • Disease-related 5-year-survival rates were 100% (group 1), 96% (group 2), 91% (group 3), and 24% (group 4), respectively.
  • The results confirm the favorable prognoses of these primary cutaneous CD30(+) lymphoproliferative disorders and underscore that LyP and primary cutaneous CD30(+) lymphomas are closely related conditions.
  • Multiagent chemotherapy is only indicated for patients with full-blown or developing extracutaneous disease; it is never or rarely indicated for patients with skin-limited CD30(+) lymphomas. (Blood.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / diagnosis. Lymphoma, T-Cell, Cutaneous / therapy. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Algorithms. Antigens, CD / analysis. Antigens, CD30 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Netherlands. Practice Guidelines as Topic. Skin / immunology. Skin / pathology. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845893.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30
  •  go-up   go-down


2. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res; 2009 Oct 1;15(19):6217-24
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients with CD30(+) primary cutaneous anaplastic large cell lymphoma (pc-ALCL), lymphomatoid papulosis (LyP), or transformed mycosis fungoides (T-MF).
  • Overall, clinical benefit of SGN-30, as assessed by achieving a response to therapy or stable disease (CR + PR + stable disease), was shown by 87% of patients during the study, including all patients with pc-ALCL or LyP and two thirds of patients with T-MF or with multiple clinical diagnoses.
  • CONCLUSIONS: SGN-30 was clinically active in 16 of 23 patients with heavily pretreated pc-ALCL, LyP, and T-MF and was well tolerated in this study.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Large-Cell, Anaplastic / therapy. Lymphoproliferative Disorders / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Algorithms. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Dose-Response Relationship, Drug. Female. Humans. Immunotherapy / methods. Male. Middle Aged. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789316.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00099255
  • [Grant] United States / PHS HHS / / K24
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / SGN-30 monoclonal antibody
  •  go-up   go-down


3. Kadin ME: Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park); 2009 Nov 30;23(13):1158-64
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary cutaneous CD30+ T-cell lymphoproliferative disorders (PCLPDs) are the second most common type of cutaneous T-cell lymphoma.
  • These disorders comprise a spectrum of clinically benign lymphomatoidpapulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma (ALCL).
  • The peak incidence of LyP is in the 5th decade of life, and the incidence of primary cutaneous ALCL peaks in the 6th decade, but children are also affected.
  • Both LyP and primary cutaneous ALCL have an excellent prognosis.
  • However, LyP is associated with development of malignant lymphoma (mycosis fungoides, Hodgkin lymphoma, or ALCL) in 20% of cases, and also with an increased risk of non-lymphoid cancers.
  • The diagnosis of LyP is difficult and often delayed.
  • Correlation of clinical findings with histopathology and immunopathology (stains for ALK kinase, epithelial membrane antigen, and cutaneous lymphocyte antigen) are important to achieve a correct diagnosis.
  • When a diagnosis of CD30+ PCLPD is established, minimal clinical staging is required.
  • Low-dose methotrexate (10-25 mg weekly) is the most effective therapy for PCLPD but is usually reserved for aggressive cases of LyP and multifocal lesions of cutaneous ALCL Many patients with LyP can be followed expectantly, with special attention to changes in character of the skin lesions or development of lymphadenopathy.
  • Extracutaneous spread of disease is an indication for multiagent chemotherapy.
  • Other treatment alternatives are discussed.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphoma, Primary Cutaneous Anaplastic Large Cell / drug therapy. Methotrexate / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antigens, CD30 / metabolism. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043465.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR018757
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 32
  •  go-up   go-down


Advertisement
4. Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M, Ruoslahti E: Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine; 2009 Mar;5(1):73-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The targeting was accomplished with two peptides, CREKA and LyP-1 (CGNKRTRGC).
  • FAM-LyP-1-abraxane co-localized with extravascular islands expressing its receptor, p32.
  • Self-assembled mixed micelles carrying the homing peptide and the label on different subunits accumulated in the same areas of tumors as LyP-1-abraxane, showing that Lyp-1 can deliver intact nanoparticles into extravascular sites.
  • LyP-1-abraxane produced a statistically highly significant inhibition of tumor growth compared with untargeted abraxane.
  • These results show that nanoparticles can be effectively targeted into extravascular tumor tissue and that targeting can enhance the activity of a therapeutic nanoparticle.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5696-706 [16740707.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):932-6 [17215365.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):319-31 [17458507.001]
  • [Cites] Bioconjug Chem. 2008 Aug;19(8):1570-8 [18611045.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7210-8 [18757437.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1359-64 [10581076.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Med. 2002 Jul;8(7):751-5 [12053175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12617-21 [12235356.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):393-403 [14667506.001]
  • [Cites] Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):293-310 [15197330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6 [15197262.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Sep 22;56(11):1537-63 [15350288.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):806-13 [15510161.001]
  • [Cites] Science. 1985 Mar 1;227(4690):1059-61 [3975602.001]
  • [Cites] Cancer Metastasis Rev. 1990 Nov;9(3):253-66 [2292138.001]
  • [Cites] J Exp Med. 1994 Jun 1;179(6):1809-21 [8195709.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):529-45 [15722162.001]
  • [Cites] Langmuir. 2005 Apr 12;21(8):3279-90 [15807565.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7794-803 [16172456.001]
  • [Cites] Curr Pharm Des. 2005;11(28):3655-60 [16305501.001]
  • [Cites] J Control Release. 2005 Dec 5;109(1-3):77-85 [16271792.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1317-24 [16489089.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2800-4 [16476999.001]
  • (PMID = 18829396.001).
  • [ISSN] 1549-9642
  • [Journal-full-title] Nanomedicine : nanotechnology, biology, and medicine
  • [ISO-abbreviation] Nanomedicine
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115410; United States / NCI NIH HHS / CA / U54 CA119335; United States / NCI NIH HHS / CA / CA124427-02; United States / NCI NIH HHS / CA / CA115410-01; United States / NCI NIH HHS / CA / R01 CA115410-01; United States / NCI NIH HHS / CA / CA104898-01A20002; United States / NCI NIH HHS / CA / R01 CA115410; United States / NCI NIH HHS / CA / U54 CA119335-010001; United States / NCI NIH HHS / CA / CA124427; United States / NCI NIH HHS / CA / P01 CA104898; United States / NHLBI NIH HHS / HL / HL080718; United States / NHLBI NIH HHS / HL / U01 HL080718; United States / NCI NIH HHS / CA / R01 CA124427-02; United States / NCI NIH HHS / CA / CA104898; United States / NHLBI NIH HHS / HL / U01 HL080718-01; United States / NCI NIH HHS / CA / CA119335-010001; United States / NCI NIH HHS / CA / P01 CA104898-01A20002; United States / NCI NIH HHS / CA / CA19335; United States / NCI NIH HHS / CA / R01 CA124427
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Drug Carriers; 0 / Peptides; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS170275; NLM/ PMC2824435
  •  go-up   go-down


5. Laube S, Shah F, Marsden J: Consequences of misdiagnosis of lymphomatoid papulosis. Eur J Cancer Care (Engl); 2006 May;15(2):194-8
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consequences of misdiagnosis of lymphomatoid papulosis.
  • We report two patients with lymphomatoid papulosis (LyP), who were initially diagnosed as systemic T-cell lymphoma.
  • Consequently, both patients were unnecessarily treated with multi-agent chemotherapy, radiotherapy and stem cell/bone marrow transplants and sustained long-term adverse effects.
  • The clinical and histological features of LyP are described and appropriate management discussed in detail.
  • Factors leading to the unnecessary treatment of both patients are examined and several learning points highlighted such as the importance of a multidisciplinary approach.
  • [MeSH-major] Diagnostic Errors. Lymphoma, T-Cell, Cutaneous / diagnosis. Lymphomatoid Papulosis / diagnosis
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643267.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Luo G, Yu X, Jin C, Yang F, Fu D, Long J, Xu J, Zhan C, Lu W: LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm; 2010 Jan 29;385(1-2):150-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
  • Active tumor targeting by biodegradable nanoparticles has been widely studied for cancer diagnosis and therapy.
  • However, target-specific nanoparticles for drug delivery to lymphatic metastases have not been reported yet due to the lack of specific markers in the tumor lymphatics.
  • Recently, peptide LyP-1 has been recognized for its specific home to tumors and their lymphatics.
  • In this study, we tested the possibility of LyP-1 serving as a target-specific peptide of PEG-PLGA nanoparticles to tumor lymph metastases.
  • LyP-1 was synthesized by using Boc-protected amino acids.
  • LyP-1 with sulfhydryl group was conjugated to the maleimide function located at the distal end of PEG surrounding the nanoparticle surface.
  • LyP-1-conjugated PEG-PLGA nanoparticle (LyP-1-NPs) had a round and regular shape with a diameter around 90 nm.
  • In vitro, cellular uptake of LyP-1-NPs was about four times of that of PEG-PLGA nanoparticles without LyP-1 (NPs).
  • In vivo, the uptake of LyP-1-NPs in metastasis lymph nodes was about eight times of that of NPs.
  • This study indicates that LyP-1-NP is a promising carrier for target-specific drug delivery to lymphatic metastatic tumors.
  • [MeSH-major] Antineoplastic Agents / metabolism. Drug Carriers. Lymph Nodes / metabolism. Maleimides / chemistry. Nanoparticles. Pancreatic Neoplasms / metabolism. Peptides, Cyclic / metabolism. Polyethylene Glycols / chemistry. Polyglactin 910 / chemistry

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19825404.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / LyP-1 peptide; 0 / Maleimides; 0 / Peptides, Cyclic; 0 / poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer; 30IQX730WE / Polyethylene Glycols; 34346-01-5 / Polyglactin 910
  •  go-up   go-down


7. Kagaya M, Kondo S, Kamada A, Yamada Y, Matsusaka H, Jimbow K: Localized lymphomatoid papulosis. Dermatology; 2002;204(1):72-4
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized lymphomatoid papulosis.
  • A 50-year-old Japanese male visited our clinic in April 1999 with a 2-year history of self-healing, reddish papules on his right palm.
  • A biopsy specimen showed a wedge-shaped, dense dermal infiltrate consisting of variously sized mononuclear lymphoid cells mixed with few large CD30-positive cells and inflammatory cells, suggesting the diagnosis of regional lymphomatoid papulosis (LyP).
  • Only 5 cases of LyP presenting in a regional distribution have been reported previously.
  • Although the etiology of localized LyP remains unknown, considering that 2 of 5 reported patients developed widespread lesions regional LyP may be the initial presentation of typical LyP.
  • [MeSH-major] Lymphomatoid Papulosis / drug therapy. Lymphomatoid Papulosis / pathology
  • [MeSH-minor] Administration, Topical. Biopsy, Needle. Drug Therapy, Combination. Follow-Up Studies. Humans. Immunohistochemistry. Injections, Subcutaneous. Interferon-gamma / administration & dosage. Male. Middle Aged. Severity of Illness Index. Steroids / administration & dosage. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 11834855.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Steroids; 82115-62-6 / Interferon-gamma
  • [Number-of-references] 11
  •  go-up   go-down


8. Mäkelä AR, Matilainen H, White DJ, Ruoslahti E, Oker-Blom C: Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides. J Virol; 2006 Jul;80(13):6603-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells and vasculature offer specific targets for the selective delivery of therapeutic genes.
  • LyP-1, F3, and CGKRK tumor-homing peptides, originally identified by in vivo screening of phage display libraries, were fused to the transmembrane anchor of vesicular stomatitis virus G protein and displayed on the baculoviral surface.
  • The LyP-1 peptide inhibited viral binding to MDA-MB-435 cells with a greater magnitude and specificity than the CGKRK and F3 peptides.
  • The internalization of each virus was inhibited by ammonium chloride treatment, suggesting the use of a similar endocytic entry route.
  • The LyP-1 and F3 peptides showed an apparent inhibitory effect in transduction of HepG2 cells with the corresponding display viruses.
  • Together, these results imply that the efficiency of baculovirus-mediated gene delivery can be significantly enhanced in vitro when tumor-targeting ligands are used and therefore highlight the potential of baculovirus vectors in cancer gene therapy.
  • [MeSH-minor] Breast Neoplasms / genetics. Breast Neoplasms / therapy. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / therapy. Cell Line, Tumor. Genetic Therapy. Humans. Peptide Library. Protein Binding / drug effects. Protein Binding / genetics. Vesicular stomatitis Indiana virus / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Chem. 1999 Mar;380(3):393-5 [10223343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):127-32 [9874783.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1121-9 [15564143.001]
  • [Cites] Curr Gene Ther. 2004 Dec;4(4):457-67 [15578994.001]
  • [Cites] Exp Physiol. 2005 Jan;90(1):27-31 [15542621.001]
  • [Cites] J Virol. 2005 Mar;79(5):2720-8 [15708991.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):529-45 [15722162.001]
  • [Cites] J Virol. 2005 Mar;79(6):3639-52 [15731258.001]
  • [Cites] J Gene Med. 2005 Mar;7(3):325-33 [15521052.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):567-75 [15877075.001]
  • [Cites] J Virol. 2000 Mar;74(5):2239-46 [10666254.001]
  • [Cites] Gene Ther. 2000 Jan;7(2):110-4 [10673715.001]
  • [Cites] J Gene Med. 1999 Mar-Apr;1(2):93-102 [10738573.001]
  • [Cites] Gene Ther. 2000 Sep;7(17):1499-504 [11001370.001]
  • [Cites] J Virol. 2001 Jan;75(2):961-70 [11134309.001]
  • [Cites] Virology. 2001 Jan 5;279(1):343-53 [11145915.001]
  • [Cites] Exp Mol Med. 2001 Mar 31;33(1):46-53 [11322486.001]
  • [Cites] Nat Biotechnol. 2001 May;19(5):451-5 [11329015.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):871-81 [11387053.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 15;284(3):777-84 [11396970.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 30;289(2):444-50 [11716493.001]
  • [Cites] Liver. 2002 Feb;22(1):15-22 [11906614.001]
  • [Cites] Trends Biotechnol. 2002 Apr;20(4):173-80 [11906750.001]
  • [Cites] J Biotechnol. 2002 May 23;95(3):269-75 [12007867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7444-9 [12032302.001]
  • [Cites] Nat Med. 2002 Jul;8(7):751-5 [12053175.001]
  • [Cites] Mol Ther. 2002 Jul;6(1):5-11 [12095297.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12617-21 [12235356.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1693-9 [12457283.001]
  • [Cites] J Pharm Sci. 2003 Feb;92(2):203-17 [12532370.001]
  • [Cites] Drug Discov Today. 2002 Nov 15;7(22):1138-43 [12546857.001]
  • [Cites] Am J Pharmacogenomics. 2003;3(1):53-63 [12562216.001]
  • [Cites] J Virol. 2003 Sep;77(18):9799-808 [12941888.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3513-21 [9920897.001]
  • [Cites] J Gene Med. 2005 Jul;7(7):860-8 [15712348.001]
  • [Cites] J Virol. 2005 Dec;79(24):15452-9 [16306616.001]
  • [Cites] Gene Ther. 2006 Feb;13(4):304-12 [16267571.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):853-62 [14599820.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):871-8 [14638862.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Arch Virol. 2004 Jan;149(1):51-60 [14689275.001]
  • [Cites] Technol Cancer Res Treat. 2004 Feb;3(1):77-84 [14750896.001]
  • [Cites] Mol Ther. 2004 Feb;9(2):282-91 [14759812.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):389-93 [15070086.001]
  • [Cites] Assay Drug Dev Technol. 2003 Dec;1(6):801-10 [15090226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6 [15197262.001]
  • [Cites] Brief Funct Genomic Proteomic. 2003 Oct;2(3):244-53 [15239927.001]
  • [Cites] J Virol. 2004 Aug;78(16):8663-72 [15280475.001]
  • [Cites] Cell. 1986 Sep 12;46(6):929-37 [3019557.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):1957-69 [2824524.001]
  • [Cites] Virology. 1988 Mar;163(1):33-42 [3279702.001]
  • [Cites] J Cell Biol. 1988 Jul;107(1):89-99 [2839523.001]
  • [Cites] Science. 1989 Mar 31;243(4899):1728-30 [2648574.001]
  • [Cites] J Cell Biol. 1993 Sep;122(6):1185-96 [8397214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10099-103 [7479733.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2348-52 [8637876.001]
  • [Cites] Hum Gene Ther. 1996 Oct 20;7(16):1937-45 [8930653.001]
  • [Cites] Mol Biol Rep. 1996;23(3-4):191-5 [9112228.001]
  • [Cites] Mol Psychiatry. 1996 Dec;1(6):423 [9154238.001]
  • [Cites] Hum Gene Ther. 1997 Nov 20;8(17):2011-8 [9414250.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Biotechnol Bioeng. 2004 Dec 5;88(5):643-51 [15472927.001]
  • (PMID = 16775347.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptide Library; 0 / Peptides
  • [Other-IDs] NLM/ PMC1488948
  •  go-up   go-down


9. Ghiggeri GM, Bleid D, Garaventa A, Coccia C, Gambini C, Caridi G, Perfumo F: Recurrent lymphomatoid papulosis associated with nephrotic syndrome. An occurrence of uncertain origin. Pediatr Nephrol; 2009 Jan;24(1):189-92
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent lymphomatoid papulosis associated with nephrotic syndrome. An occurrence of uncertain origin.
  • We report on a 10-year-old child with nephrotic syndrome who developed recurrent lymphomatoid papulosis (LYP) 60 months after the first episode of proteinuria.
  • LYP appeared when the child was taking low-dose cyclosporin and disappeared after the drug was replaced by prednisone at doses utilized for nephrotic syndrome (2 mg/kg).
  • During the tapering of steroids, when the child was treated with low-dose prednisone (0.2 mg/kg), both LYP and nephrotic syndrome started again and required the reintroduction of prednisone to restore a normal clinical situation.
  • This is the first case of LYP occurring in concomitance and synchronous with nephrotic syndrome.
  • LYP was unrelated to cyclosporin (second episode after its withdrawn) but preceded the recurrence of proteinuria, suggesting a relationship with the disease activity.
  • Even though the etiology of LYP is, in this case, uncertain, it should be considered as a clinical association of nephrotic syndrome in children and also included among potential triggers of the disease.
  • [MeSH-major] Lymphomatoid Papulosis / pathology. Nephrotic Syndrome / pathology
  • [MeSH-minor] Child. Cyclosporine / therapeutic use. Dose-Response Relationship, Drug. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Prednisone / therapeutic use. Proteinuria / drug therapy. Proteinuria / etiology. Proteinuria / pathology. Recurrence

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3437-41 [8605362.001]
  • [Cites] J Clin Pathol. 2003 Jun;56(6):439-46 [12783971.001]
  • [Cites] Arch Dermatol. 2004 Apr;140(4):449-54 [15096373.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1238-47 [11961011.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1765-70 [8781433.001]
  • [Cites] Blood. 1997 Jul 1;90(1):354-71 [9207472.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • [Cites] Kidney Int. 2006 Jun;69(12):2251-60 [16672913.001]
  • [Cites] Eur J Pediatr. 1997 Mar;156(3):239-42 [9083769.001]
  • [Cites] Am J Med. 1971 Jan;50(1):56-66 [5539577.001]
  • [Cites] Arch Dermatol. 1968 Jan;97(1):23-30 [5634442.001]
  • [Cites] Neth J Med. 1981;24(3):114-9 [7254442.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):668-75 [16546591.001]
  • [Cites] Nephrol Dial Transplant. 2003 Feb;18(2):245-8 [12543875.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] J Am Soc Nephrol. 1999 Mar;10(3):529-37 [10073603.001]
  • [Cites] J Am Soc Nephrol. 1997 May;8(5):848-52 [9176859.001]
  • [Cites] N Engl J Med. 1992 Apr 23;326(17):1115-22 [1532439.001]
  • (PMID = 18026996.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; VB0R961HZT / Prednisone
  •  go-up   go-down


10. Li X, Jin Q, Chen T, Zhang B, Zheng R, Wang Z, Zheng H: LyP-1 ultrasonic microbubbles targeting to cancer cell as tumor bio-acoustics markers or drug carriers: targeting efficiency evaluation in, microfluidic channels. Conf Proc IEEE Eng Med Biol Soc; 2009;2009:463-6
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LyP-1 ultrasonic microbubbles targeting to cancer cell as tumor bio-acoustics markers or drug carriers: targeting efficiency evaluation in, microfluidic channels.
  • Using ultrasonic contrast microbubbles as acoustic biomarkers and drug carrier vehicles by conjugating tumor specific antibody to microbubbles has shown great potential in ultrasonic tumor molecular imaging or drug-delivery and therapy.
  • In this study, we developed a novel method to evaluate the targeting capability and efficiency of microbubbles to cells, and more specifically, microbubbles binding LyP-1 (a cyclic nonapeptide acid peptide) target to cancer cell within a microfluidic system.
  • The system provides a useful low-cost high efficient in vitro platform for studying microbubble-cell interaction for ultrasonic tumor molecular imaging or drug-delivery and therapy.
  • [MeSH-minor] Cell Line, Tumor. Drug Delivery Systems / instrumentation. Drug Delivery Systems / methods. Equipment Design. Equipment Failure Analysis. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19964739.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LyP-1 peptide; 0 / Peptides, Cyclic
  •  go-up   go-down


11. Rifkin S, Valderrama E, Lipton JM, Karayalcin G: Lymphomatoid papulosis and Ki-1+ anaplastic large cell lymphoma occurring concurrently in a pediatric patient. J Pediatr Hematol Oncol; 2001 Jun-Jul;23(5):321-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis and Ki-1+ anaplastic large cell lymphoma occurring concurrently in a pediatric patient.
  • Lymphomatoid papulosis (LyP) is a benign, self-healing, papular eruption that can wax and wane over the course of time.
  • Transformation to T-cell lymphoma has been well documented in 10% to 20% of adults with LyP, but there are have been no cases reported in patients younger than age 26 years.
  • We describe the first pediatric patient, a 16-year-old girl, who had clinical features of LyP and concurrently was found to have a lesion diagnosed as Ki-1+ anaplastic large cell lymphoma.
  • After treatment with chemotherapy, she has been in continuous remission for 16 months.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / complications. Lymphomatoid Papulosis / complications
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Clone Cells / chemistry. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Neoplasm Invasiveness. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / pathology. Prednisone / administration & dosage. Remission Induction. Shoulder. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464993.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Perna AG, Jones DM, Duvic M: Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma; 2004 Dec;5(3):190-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel.
  • Lymphomatoid papulosis (LyP) is a lymphoproliferative disorder that exists on a spectrum of diseases with cutaneous CD30+ anaplastic large-cell lymphoma (ALCL).
  • Multiple treatment options are available, although none are curative.
  • The typical age of onset for LyP is in the third and fourth decades, but it has been seen occasionally in children.
  • Lymphomatoid papulosis is associated with primary cutaneous ALCL and other lymphoproliferative malignancies, but is rarely associated with extranodal systemic ALCL.
  • A 43-year-old man developed lymphomatoid papulosis lesions at 3 years of age, which persisted into adulthood, and he later developed ALCL of the duodenum.
  • Treatment with standard CHOP (cyclophosphamide/doxorubicin/vincristine/prednisolone) chemotherapy resulted in complete remission of his gastrointestinal lymphoma and temporary improvement of his skin lesions.
  • However, the LyP relapsed and proved refractory to psoralen plus ultraviolet-A phototherapy, and was only temporarily and partially responsive to bexarotene and denileukin diftitox.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use. Intestinal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphomatoid Papulosis / pathology. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Adult. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage


13. Krathen RA, Ward S, Duvic M: Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology; 2003;206(2):142-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bexarotene is a new treatment option for lymphomatoid papulosis.
  • BACKGROUND: Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma.
  • OBJECTIVE: To determine whether bexarotene is effective in treating LyP.
  • METHODS: Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene.
  • RESULTS: A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients.
  • CONCLUSIONS: Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.
  • [MeSH-major] Anticarcinogenic Agents / administration & dosage. Lymphomatoid Papulosis / drug therapy. Tetrahydronaphthalenes / administration & dosage

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12592082.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / K24 CA-86815
  • [Publication-type] Case Reports; Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  •  go-up   go-down


14. Drews R, Samel A, Kadin ME: Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg; 2000 Jun;19(2):109-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin.
  • It is now generally accepted that primary CD30+ cutaneous lymphomas comprise a clinical and morphologic spectrum in which a clear distinction between lymphomatoid papulosis (LyP) and lymphoma cannot always be made.
  • Management varies from observation in patients who have relatively asymptomatic, spontaneously remitting disease (as in LyP) to multiagent chemotherapy regimens with or without autologous stem cell transplantation in patients whose disease has spread to involve extracutaneous sites other than regional lymph nodes (as in disseminated CD30+ lymphoma).
  • The importance of clinicopathologic correlation cannot be overemphasized, because lesions with clinically "benign" behavior may appear "malignant" by pathology, and failure to interpret pathologic findings in accordance with the patient's clinical history and physical exam can result in unnecessary, overly aggressive, and potentially harmful treatments.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphomatoid Papulosis / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30 / blood. Diagnosis, Differential. Genotype. Humans. Immunophenotyping. Lymphoma, Large-Cell, Anaplastic / diagnosis. Mycosis Fungoides / diagnosis. Phenotype. Pityriasis Lichenoides / diagnosis. Recurrence. Remission Induction. Survival Analysis. T-Lymphocytes, Helper-Inducer / pathology

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10892712.001).
  • [ISSN] 1085-5629
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Number-of-references] 43
  •  go-up   go-down


15. Dawn G, Morrison A, Morton R, Bilsland D, Jackson R: Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Clin Exp Dermatol; 2003 Nov;28(6):620-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
  • We describe the case of a 37-year-old female with a history of psoriasiform dermatitis who presented with multicentric primary cutaneous CD30-positive anaplastic large T cell lymphoma (ALCL).
  • Despite aggressive systemic therapy, the patient suffered multiple relapses and the lymphoma spread to cervical and inguinal lymph nodes.
  • Later in her clinical course it was appreciated that she was also suffering from lymphomatoid papulosis (LyP).
  • The case illustrates the overlapping clinical, histological and immunophenotypic features of ALCL and LyP, conditions which represent a spectrum of CD30-positive lymphoproliferative disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphomatoid Papulosis / drug therapy. Neoplasms, Multiple Primary / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interprofessional Relations. Patient Care Team. Polymerase Chain Reaction / methods. Prednisolone / administration & dosage. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616830.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; CHOP protocol; IVEP protocol
  •  go-up   go-down


16. Yazawa N, Kondo S, Kagaya M, Yazawa H, Minamitsuji Y, Jimbow K: Successful treatment of a patient with lymphomatoid papulosis by methotrexate. J Dermatol; 2001 Jul;28(7):373-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a patient with lymphomatoid papulosis by methotrexate.
  • We report a case of lymphomatoid papulosis (LyP) that occurred in a 44-year-old Japanese male patient.
  • Reddish papules with a small number of pustules and nodules were observed on the extremities, chest and upper back.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Lymphomatoid Papulosis / diagnosis. Lymphomatoid Papulosis / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Antigens, CD30 / immunology. Back. Diagnosis, Differential. Extremities. Humans. Male. Thorax

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11510505.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Bergstrom JS, Jaworsky C: Topical methotrexate for lymphomatoid papulosis. J Am Acad Dermatol; 2003 Nov;49(5):937-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical methotrexate for lymphomatoid papulosis.
  • Lymphomatoid papulosis is a lymphoproliferative disease characterized by recurrent papules, nodules, or plaques that spontaneously involute within several weeks.
  • Despite having a histologically malignant-appearing infiltrate, patients with lymphomatoid papulosis have a clinically benign course.
  • Several treatment options have been described for the management of lymphomatoid papulosis.
  • [MeSH-major] Lymphomatoid Papulosis / drug therapy. Methotrexate / administration & dosage

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14576686.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Su LD, Duncan LM: Lymphoma- and leukemia-associated cutaneous atypical CD30+ T-cell reactions. J Cutan Pathol; 2000 May;27(5):249-54
Hazardous Substances Data Bank. CARBAMAZEPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous CD30+ lymphoid infiltrates appear cytologically atypical and occasionally may be misinterpreted as recurrent disease when they occur in patients treated for other primary hematologic malignancies.
  • One patient with B-cell lymphoma and another with myeloid leukemia developed cutaneous eruptions after chemotherapy displaying highly atypical perivascular lymphoid cells on histology that mimicked recurrent disease.
  • We discuss the differential diagnosis of atypical CD30+ infiltrates in this setting, which include recurrent lymphoma or myeloid leukemia, primary cutaneous anaplastic large cell lymphoma (ALCL), lymphomatoid papulosis (LyP), carbamazepine-induced CD30+ pseudolymphoma, viral infection and an atypical eruption of lymphocyte recovery.
  • [MeSH-minor] Carbamazepine / adverse effects. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphomatoid Papulosis / diagnosis. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Pseudolymphoma / chemically induced. Pseudolymphoma / diagnosis. Skin Diseases, Viral / diagnosis

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10847550.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antigens, CD30; 33CM23913M / Carbamazepine
  •  go-up   go-down


19. Herron MD, Bohnsack JF, Vanderhooft SL: Septic, CD-30 positive febrile ulceronecrotic pityriasis lichenoides et varioliformis acuta. Pediatr Dermatol; 2005 Jul-Aug;22(4):360-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sepsis delayed definitive treatment of the underlying cutaneous disease for 2 weeks.
  • Combined therapy with methotrexate and cyclosporin caused remission of the process.
  • Although immunohistochemistry revealed CD-30 positive cells, suggesting the diagnosis of lymphomatoid papulosis, the histopathology was most compatible with pityriasis lichenoides et varioliformis acuta.
  • Elevated soluble interleukin-2 receptor levels reflected marked T-cell activation, and the downward trend of the levels during treatment coincided with clinical regression of this inflammatory dermatosis.
  • [MeSH-major] Antigens, CD30 / analysis. Fever / etiology. Pityriasis Lichenoides / diagnosis. Sepsis / microbiology. Skin Ulcer / etiology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Bacteremia / drug therapy. Bacteremia / microbiology. Candida / isolation & purification. Child. Drug Therapy, Combination. Female. Fungemia / drug therapy. Fungemia / microbiology. Humans. Immunosuppressive Agents / therapeutic use. Lymphocytes / immunology. Lymphocytes / metabolism. Pseudomonas aeruginosa / isolation & purification. Receptors, Interleukin-2 / blood. Respiratory Distress Syndrome, Adult / therapy. Staphylococcus epidermidis / isolation & purification


20. Tenikoff D, Murphy KJ, Le M, Howe PR, Howarth GS: Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. J Gastroenterol; 2005 Apr;40(4):361-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease.
  • We investigated the effect of pretreatment with Lyprinol (LYP) on experimentally induced inflammatory bowel disease (IBD) in mice.
  • METHODS: Male C57BL/6 mice (aged 6 weeks) were gavaged daily for 13 days with (150 microl) olive oil (OO; n = 7), fish oil (FO; n = 8), or LYP (n = 8).
  • Body weight and disease activity index (DAI) scores were recorded daily.
  • RESULTS: LYP treatment significantly (P < 0.05) reduced body weight loss, DAI scores, crypt area losses, and cecum and colon weights, compared with FO treatment.
  • MPO activity was not significantly affected by any treatment.
  • [MeSH-major] Colitis, Ulcerative / prevention & control. Lipids / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Body Weight / drug effects. Colon / drug effects. Colon / enzymology. Colon / pathology. Dextran Sulfate / toxicity. Disease Models, Animal. Disease Progression. Drug Therapy, Combination. Fish Oils / administration & dosage. Fish Oils / therapeutic use. Follow-Up Studies. Male. Mice. Mice, Inbred C57BL. Olive Oil. Organ Size / drug effects. Peroxidase / metabolism. Plant Oils / administration & dosage. Plant Oils / therapeutic use. Plasma Substitutes / toxicity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870972.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fish Oils; 0 / Lipids; 0 / Olive Oil; 0 / Plant Oils; 0 / Plasma Substitutes; 0 / lyprinol; 9042-14-2 / Dextran Sulfate; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


21. Granel B, Serratrice J, Swiader L, Horshowski N, Blaise D, Vey N, Metras D, Habib G, Disdier P, Weiller PJ: Lymphomatoid papulosis associated with both severe hypereosinophilic syndrome and CD30 positive large T-cell lymphoma. Cancer; 2000 Nov 15;89(10):2138-43
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis associated with both severe hypereosinophilic syndrome and CD30 positive large T-cell lymphoma.
  • BACKGROUND: Previous reports have found an association between lymphomatoid papulosis and hypereosinophilic syndrome, as well as lymphomatoid papulosis and lymphoma.
  • METHODS: The authors followed the clinical course of a 64-year-old man with lymphomatoid papulosis associated with severe hypereosinophilic syndrome complicated by involvement of the lungs and heart.
  • The bone marrow biopsy was typical of hypereosinophilic syndrome associated with fibrosis, with focal lymphomatous infiltrates comprised of large cells resembling the type A cells of lymphomatoid papulosis.
  • Complete remission of the lymphoma was obtained with chemotherapy.
  • Lymphomatoid papulosis belongs to the spectrum of CD30 positive lymphoproliferative disorders and CD30 positive lymphocytes of lymphomatoid papulosis are known to have a Th2 profile with possible secretion of eosinopoietic cytokines.
  • [MeSH-major] Antigens, CD30 / analysis. Hypereosinophilic Syndrome / complications. Lymphoma, T-Cell / complications. Lymphomatoid Papulosis / complications

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11066056.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


22. Barr AJ: Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem; 2010 Oct;2(10):1563-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.
  • Several 'classical' protein tyrosine phosphatases are attractive therapeutic targets, including PTP1B for obesity and Type II diabetes; SHP2 for cancer and Lyp for rheumatoid arthritis.
  • [MeSH-major] Drug Discovery / methods. Enzyme Inhibitors / chemistry. Enzyme Inhibitors / pharmacology. Protein Tyrosine Phosphatases / antagonists & inhibitors. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Animals. Autoimmune Diseases / drug therapy. Autoimmune Diseases / enzymology. Diabetes Mellitus, Type 2 / drug therapy. Diabetes Mellitus, Type 2 / enzymology. Humans. Models, Molecular. Neoplasms / drug therapy. Neoplasms / enzymology. Obesity / drug therapy. Obesity / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21426149.001).
  • [ISSN] 1756-8927
  • [Journal-full-title] Future medicinal chemistry
  • [ISO-abbreviation] Future Med Chem
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / ; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


23. Quaglino P, Fierro MT, Rossotto GL, Savoia P, Bernengo MG: Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol; 2004 Feb;150(2):327-36
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
  • PATIENTS AND METHODS: Forty-four CTCL patients [17 Sézary syndrome (SS); 26 mycosis fungoides (MF), stage IIB-IV or with peripheral blood involvement; one MF associated with lymphomatoid papulosis (LyP)] were enrolled in this pilot cohort study.
  • According to the treatment group, the RR of the FAMP-ECP group (63.2%) was significantly higher than that of the FAMP monotherapy group (24%; P=0.021).
  • No statistically significant difference was found in time-to-progression (TTP) or survival by therapy group, even if the TTP of the patients treated with the FAMP-ECP combination therapy was higher (median 13 vs. 7 months).
  • CONCLUSIONS: FAMP confirms its clinical activity as a single agent in SS; conversely, FAMP results do not compare favourably with other therapeutic approaches for advanced stage MF patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Mycosis Fungoides / drug therapy. Photopheresis / methods. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy. Vidarabine Phosphate / analogs & derivatives. Vidarabine Phosphate / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Cohort Studies. Female. Humans. Lymphocyte Subsets. Male. Middle Aged. Phenotype. Pilot Projects. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • Genetic Alliance. consumer health - Sezary syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14996105.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate
  •  go-up   go-down


24. Wu S, Bottini M, Rickert RC, Mustelin T, Tautz L: In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation. ChemMedChem; 2009 Mar;4(3):440-4
Hazardous Substances Data Bank. (L)-Tryptophan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A gain-of-function mutant of the lymphoid phosphatase Lyp (PTPN22) has recently been implicated in type 1 diabetes and other autoimmune diseases, suggesting that small-molecule inhibitors of Lyp could be useful for the treatment of autoimmunity.
  • Two different docking algorithms, FlexX and ICM, were used to screen a library of 'drug-like' molecules against two different 3D structures, representing the catalytic site of Lyp in both the inactive 'open' and active 'closed' conformations.
  • The top-scoring compounds of each VLS run were tested for their inhibitory activity against recombinant Lyp.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2004 Sep;75(3):504-7 [15273934.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jun 20;44(25):3814-39 [15900534.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):337-8 [15004560.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:209-34 [11807171.001]
  • [Cites] Annu Rev Immunol. 2008;26:29-55 [18303998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19767-72 [18056643.001]
  • [Cites] Methods. 2007 Jul;42(3):250-60 [17532512.001]
  • [Cites] Expert Opin Ther Targets. 2006 Feb;10(1):157-77 [16441235.001]
  • [Cites] Bioinformatics. 2006 Jan 15;22(2):195-201 [16301204.001]
  • [Cites] Hum Immunol. 2005 Jan;66(1):60-4 [15620463.001]
  • [Cites] J Chem Inf Comput Sci. 1999 Sep-Oct;39(5):897-902 [10529988.001]
  • [Cites] Blood. 1999 Mar 15;93(6):2013-24 [10068674.001]
  • [Cites] Proteins. 1997;Suppl 1:215-20 [9485515.001]
  • [Cites] J Mol Biol. 1996 Aug 23;261(3):470-89 [8780787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Mar;77(3):1311-5 [6246487.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1317-9 [16273109.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):330-7 [15208781.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • (PMID = 19177473.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI053585-05; United States / NCI NIH HHS / CA / CA132121; United States / NIAID NIH HHS / AI / R01 AI053585-05; United States / NCI NIH HHS / CA / R21 CA132121; United States / NIAID NIH HHS / AI / AI053585; United States / NIAID NIH HHS / AI / R01 AI053585; United States / NCI NIH HHS / CA / R21 CA132121-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzamides; 0 / Ligands; 0 / Recombinant Proteins; 0 / Small Molecule Libraries; 8DUH1N11BX / Tryptophan; EC 3.1.3.48 / PTPN22 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 22
  • [Other-IDs] NLM/ NIHMS287789; NLM/ PMC3102533
  •  go-up   go-down


25. Schmuth M, Topar G, Illersperger B, Kowald E, Fritsch PO, Sepp NT: Therapeutic use of interferon-alpha for lymphomatoid papulosis. Cancer; 2000 Oct 1;89(7):1603-10
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of interferon-alpha for lymphomatoid papulosis.
  • BACKGROUND: Lymphomatoid papulosis is a primary cutaneous, CD30 positive lymphoproliferative disorder with the potential to transform into systemic, malignant lymphoma.
  • Therapeutic strategies for patients with lymphomatoid papulosis have been designed to prevent transformation but have proved to be either inefficacious or limited by side effects.
  • METHODS: The authors compared the clinical, histologic, and immunohistochemical features from a group of five patients receiving interferon-alpha (IFN-alpha) subcutaneously three times per week with the same features from a group of six patients receiving conventional therapy, including photochemotherapy, antibiotics, topical corticosteroids, or surgery, in an open trial.
  • RESULTS: In the IFN-alpha group, four patients showed a complete remission, and one patient showed a partial remission within a time period of 6 weeks.
  • Two patients developed disease recurrences after discontinuation of short term IFN-alpha therapy (5-7 months).
  • Thereof, one patient went into stable remission after long term IFN-alpha therapy (17 months), and one patient remains in partial remission.
  • In the control group, one patient went into spontaneous remission, two patients showed partial remission, of which one patient developed progressive disease at a later time point, whereas three patients have recurrent disease despite of treatment.
  • CONCLUSIONS: The current results indicate that the treatment with IFN-alpha of patients with lymphomatoid papulosis alters the clinical course of the disease with fewer side effects than previous regimens; however, short term treatment does not induce stable remission.
  • Therefore, prolonged treatment appears to be warranted for these patients.
  • [MeSH-major] Interferon-alpha / therapeutic use. Lymphomatoid Papulosis / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Disease Progression. Female. Humans. Immunohistochemistry. Injections, Subcutaneous. Male. Middle Aged. Phototherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11013377.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Bacterial Agents; 0 / Interferon-alpha
  •  go-up   go-down


26. Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, Bhatia SN, Sailor MJ: Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A; 2010 Jan 19;107(3):981-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant barrier to the clinical translation of systemically administered therapeutic nanoparticles is their tendency to be removed from circulation by the mononuclear phagocyte system.
  • The addition of a targeting ligand that selectively interacts with cancer cells can improve the therapeutic efficacy of nanomaterials, although these systems have met with only limited success.
  • The targeting species employed in this work is a cyclic nine-amino acid peptide LyP-1 (Cys-Gly-Asn-Lys-Arg-Thr-Arg-Gly-Cys) that binds to the stress-related protein, p32, which we find to be upregulated on the surface of tumor-associated cells upon thermal treatment.
  • Mice containing xenografted MDA-MB-435 tumors that are treated with the combined NR/LyP-1LP therapeutic system display significant reductions in tumor volume compared with individual nanoparticles or untargeted cooperative system.

  • COS Scholar Universe. author profiles.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Biochim Biophys Acta. 1985 Jan 10;812(1):55-65 [23008845.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4440-5 [10969790.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2404-7 [12089446.001]
  • [Cites] Nat Med. 2002 Jul;8(7):751-5 [12053175.001]
  • [Cites] Rheumatology (Oxford). 2002 Dec;41(12):1346-56 [12468813.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6039-44 [12716967.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54 [14597719.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6 [15197262.001]
  • [Cites] Cancer. 1977 Jun;39(6):2637-46 [872062.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2290-8 [36224.001]
  • [Cites] Cancer Res. 1984 Oct;44(10 Suppl):4853s-4856s [6205752.001]
  • [Cites] Biochim Biophys Acta. 1985 Jun 27;816(2):294-302 [3839135.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5317-24 [15958579.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Dec 14;57(15):2203-14 [16290254.001]
  • [Cites] J Am Chem Soc. 2006 Feb 15;128(6):2115-20 [16464114.001]
  • [Cites] J Phys Chem B. 2006 Apr 13;110(14):7238-48 [16599493.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] Nano Lett. 2008 May;8(5):1492-500 [18412402.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8 [18607000.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7210-8 [18757437.001]
  • [Cites] Nanomedicine. 2009 Mar;5(1):73-82 [18829396.001]
  • [Cites] Small. 2009 Mar;5(6):694-700 [19263431.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):3892-900 [19366797.001]
  • [Cites] Nat Biotechnol. 2009 Jul;27(7):643-51 [19561595.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1197-201 [10728674.001]
  • (PMID = 20080556.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124427; United States / NCI NIH HHS / CA / U54 CA119335; United States / NCI NIH HHS / CA / U54 CA119349; United States / NCI NIH HHS / CA / 5-R01-CA124427
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2824295
  •  go-up   go-down


27. Rodrigues M, McCormack C, Yap LM, Prince HM, Roberts H, Williams R, Foley P: Successful treatment of lymphomatoid papulosis with photodynamic therapy. Australas J Dermatol; 2009 May;50(2):129-32
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of lymphomatoid papulosis with photodynamic therapy.
  • A 40-year-old woman presented with a prolonged history of recurrent crops of erythematous papules and nodules on her abdomen, arms and legs.
  • Histological examination of a cutaneous biopsy revealed Type A lymphomatoid papulosis.
  • Over a 3-year period, some of the patient's lesions had proven to be resistant to treatment with topical and intralesional corticosteroids and systemic agents including methotrexate, tetracycline and nicotinamide.
  • These resistant lesions were treated with two sessions of methyl aminolevulinate photodynamic therapy given 1 week apart.
  • Review 11 months post-photodynamic therapy demonstrated complete clinical clearance at the treatment site.
  • While photodynamic therapy is considered a standard non-surgical treatment option for non-melanoma skin cancers and has been described in a number of non-oncological indications, this is the first report of its use in lymphomatoid papulosis.
  • [MeSH-major] Lymphomatoid Papulosis / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397568.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


28. Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ: Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol; 2004 Aug;17(8):946-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
  • c-Kit receptor (CD117) is expressed by erythroid, megakaryocytic, and myeloid precursors and mature mast cells and has been reported to be expressed in CD30+ lymphomas such as Hodgkin's disease and anaplastic large-cell lymphoma.
  • Imatinib mesylate, a well-established inhibitor of bcr-abl tyrosine kinase, and currently used for the treatment of patients with chronic myeloid leukemia, also inhibits c-kit receptor kinase activity.
  • In view of the possible use of imatinib as experimental therapy for patients with c-kit-positive tumors, we assessed c-kit expression in CD30+ cell lines and lymphomas.
  • c-Kit expression was also immunohistochemically assessed in 168 CD30+ lymphomas including 87 classical Hodgkin's disease, 63 anaplastic large-cell lymphoma, and 15 cutaneous anaplastic large-cell lymphoma.
  • We also studied 18 cases of lymphomatoid papulosis, a CD30+ lesion closely related to cutaneous anaplastic large-cell lymphoma.
  • Furthermore, treatment with imatinib did not inhibit proliferation of cell lines in vitro.
  • Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology. Proto-Oncogene Proteins c-kit / biosynthesis
  • [MeSH-minor] Antigens, CD30 / analysis. Antineoplastic Agents / pharmacology. Benzamides. Cell Division / drug effects. Cell Line, Tumor. Flow Cytometry. Hodgkin Disease / genetics. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Imatinib Mesylate. Immunohistochemistry. Piperazines / pharmacology. Pyrimidines / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15105813.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


29. Marschalkó M, Eros N, Holló P, Hársing J, Bottlik G, Bátai A, Csukly Z, Masszi T, Szentirmai Z, Fodor J, Kárpáti S, Matolcsy A, Csomor J: Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. Am J Dermatopathol; 2010 Oct;32(7):708-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration.
  • He had a history of lymphomatoid papulosis since childhood.
  • At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed.
  • Chemotherapy resulted in complete remission of the lymphadenopathy.
  • Four years later, systemic relapse was detected which was refractory to therapy.
  • The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily.
  • Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Male. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644462.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


30. El-Shafei A, Fadda AA, Khalil AM, Ameen TA, Badria FA: Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolodiazine and triazine analogs. Bioorg Med Chem; 2009 Jul 15;17(14):5096-105
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, in vivo evaluation of compounds 6 and 10 proved their capability to normalize the blood picture in comparison to 5-FU, a well known anticancer drug.
  • To develop a QSAR model capable of identifying the key molecular descriptors associated with the biological activity of the novel pyrazole analogs and predicting the cytotoxic effect for other novel pyrazole analogs against EAC cells, different QSAR models, using different physicochemical and topological molecular descriptors, were developed.
  • Different molecular descriptors were predicted solely from the chemical structures of 16 pyrazolo-diazine and triazine analogs following the prediction of the equilibrium molecular geometry of each analog at the DFT level using B88-LYP functional energy and double zeta valence polarized (DZVP) basis set.
  • It was found that dipole moment, excitation energy, the energy value of LUMO, solvent accessible surface area, and heat of formation were the key molecular descriptors in descriping the cytotoxic effect of those compounds against EAC.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / therapeutic use. Azo Compounds / chemistry. Azo Compounds / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Pyrazoles / chemistry. Pyrazoles / therapeutic use. Triazines / chemistry. Triazines / therapeutic use
  • [MeSH-minor] Animals. Casein Kinase II / chemistry. Casein Kinase II / metabolism. Catalytic Domain. Cell Line, Tumor. Cell Survival / drug effects. Male. Mice. Models, Molecular. Molecular Structure. Protein Binding. Quantitative Structure-Activity Relationship. Survival

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527933.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Azo Compounds; 0 / Pyrazoles; 0 / Triazines; EC 2.7.11.1 / Casein Kinase II
  •  go-up   go-down


31. von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, Fogal V, Sailor MJ, Ruoslahti E, Bhatia SN: In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem; 2008 Aug;19(8):1570-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We find that "click" chemistry allows cyclic LyP-1 targeting peptides to be specifically linked to azido-nanoparticles and to direct their binding to p32-expressing tumor cells in vitro.
  • Moreover, "click" nanoparticles are able to stably circulate for hours in vivo following intravenous administration (>5 h circulation time), extravasate into tumors, and penetrate the tumor interstitium to specifically bind p32-expressing cells in tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Jul;8(7):751-5 [12053175.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47891-7 [12372830.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):1999-2004 [12727808.001]
  • [Cites] Prog Lipid Res. 2003 Nov;42(6):463-78 [14559067.001]
  • [Cites] Biochemistry. 2003 Dec 9;42(48):14130-8 [14640680.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):741-50 [15146564.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):397-402 [15157146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9381-6 [15197262.001]
  • [Cites] Science. 1987 Oct 23;238(4826):491-7 [2821619.001]
  • [Cites] Magn Reson Med. 1993 May;29(5):599-604 [8505895.001]
  • [Cites] Bioconjug Chem. 1999 Mar-Apr;10(2):186-91 [10077466.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11593-8 [10206967.001]
  • [Cites] J Am Chem Soc. 2005 Oct 19;127(41):14518-24 [16218649.001]
  • [Cites] Chem Biol. 2005 Oct;12(10):1075-83 [16242650.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1418-23 [16244656.001]
  • [Cites] Chem Commun (Camb). 2005 Dec 14;(46):5775-7 [16307142.001]
  • [Cites] J Am Chem Soc. 2006 Feb 15;128(6):2115-20 [16464114.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):849-54 [16704226.001]
  • [Cites] Mol Imaging. 2006 Apr-Jun;5(2):122-8 [16954026.001]
  • [Cites] J Med Chem. 2006 Oct 5;49(20):6087-93 [17004722.001]
  • [Cites] Chem Commun (Camb). 2006 Aug 14;(30):3193-5 [17028740.001]
  • [Cites] Bioconjug Chem. 2006 Nov-Dec;17(6):1373-5 [17105213.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6677-86 [17121886.001]
  • [Cites] Biomaterials. 2007 Feb;28(6):1236-47 [17126900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):932-6 [17215365.001]
  • [Cites] Mol Cancer Res. 2007 Jan;5(1):11-9 [17259343.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1555-62 [17308094.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):579-84 [17335177.001]
  • [Cites] Chem Commun (Camb). 2007 Apr 14;(14):1453-5 [17389990.001]
  • [Cites] Nano Lett. 2007 Apr;7(4):874-9 [17362046.001]
  • [Cites] Chem Commun (Camb). 2007 Jun 14;(22):2249-51 [17534506.001]
  • [Cites] Nano Lett. 2007 Jun;7(6):1706-10 [17530811.001]
  • [Cites] Chem Commun (Camb). 2007 Aug 14;(30):3136-8 [17653366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54 [17875985.001]
  • [Cites] Chembiochem. 2007 Nov 5;8(16):1997-2002 [17854021.001]
  • [Cites] Chem Commun (Camb). 2008 Jan 14;(2):169-71 [18092076.001]
  • [Cites] Biomaterials. 2008 Mar;29(8):1118-26 [18035410.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91 [18272481.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):7210-8 [18757437.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):283-318 [11356986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7444-9 [12032302.001]
  • (PMID = 18611045.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA119335; United States / NCI NIH HHS / CA / CA124427-02; United States / NCI NIH HHS / CA / 1R01CA124427-01; United States / NIGMS NIH HHS / GM / T32 GM007753; United States / NCI NIH HHS / CA / R01 CA124427-02; United States / NCI NIH HHS / CA / U54 CA119335-02; United States / NCI NIH HHS / CA / U54 CA119349; United States / NCI NIH HHS / CA / CA119335-02; United States / NCI NIH HHS / CA / U54 CA119349-01; United States / NCI NIH HHS / CA / R01 CA124427
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkynes; 0 / Amines; 0 / Azides; 0 / Mitochondrial Proteins; 0 / Peptides, Cyclic; 0 / Polymers; 0 / Sulfhydryl Compounds; 0 / mitochondrial p32 protein, human
  • [Other-IDs] NLM/ NIHMS54613; NLM/ PMC2538627
  •  go-up   go-down


32. Laube S, Stephens M, Smith AG, Whittaker SJ, Tan BB: Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy. Br J Dermatol; 2005 Jun;152(6):1346-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy.
  • We report a 36-year-old man with atopic eczema who developed lymphomatoid papulosis while taking ciclosporin.
  • There are only two reports in the literature of patients taking ciclosporin to control atopic eczema who developed primary cutaneous CD30+ T-cell lymphoproliferative disorders.
  • [MeSH-major] Cyclosporine / adverse effects. Dermatitis, Atopic / drug therapy. Immunosuppressive Agents / adverse effects. Lymphomatoid Papulosis / chemically induced
  • [MeSH-minor] Adult. Humans. Male. Methotrexate / therapeutic use

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Genetic Alliance. consumer health - Eczema.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949007.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 11
  •  go-up   go-down


33. Newlove T, Loyd A, Patel R, Jelinek J, Latkowski JA: Primary cutaneous anaplastic large-cell lymphoma. Dermatol Online J; 2010;16(11):2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This entity must be distinguished from systemic ALCL with cutaneous involvement and lymphomatoid papulosis.
  • Treatment modalities include clinical monitoring, radiation therapy, and surgical excision, with systemic chemotherapy reserved for disseminated or extracutaneous disease.
  • [MeSH-major] Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antigens, CD30 / metabolism. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163153.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


34. Wolf R, Barzilai A, Davidovici B: Intertriginous lymphomatoid drug eruption. Int J Dermatol; 2010 Oct;49(10):1207-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intertriginous lymphomatoid drug eruption.
  • A 76-year-old man developed a maculopapular purpuric eruption confined to the intertriginous areas (i.e. the inguinal, gluteal, and axillary folds).
  • Two days before the eruption appeared, he had received a second course of chemotherapy consisting of cisplatinum 40 mg and gemcitabine (Gemzar) 1700 mg for the treatment of squamous cell carcinoma of the lung stage III B.
  • The histologic picture was of either lymphomatoid drug eruption or lymphomatoid papulosis.
  • The antineoplastic therapy was changed to once-weekly intravenous vinorelbine (Navelbine) 50 mg, a Vinca alkaloid, and the eruption resolved completely within two weeks without any further therapy.
  • These circumstantial evidences support the diagnosis of intertriginous drug eruption.
  • Our case is interesting and unusual in that it demonstrated a rare clinical presentation of drug eruption, namely, intertriginous drug eruption or baboon syndrome, with a histologic picture of a lymphomatoid drug eruption that can mimic lymphoma.
  • We are unaware of any earlier reported case of baboon syndrome with a histologic picture of lymphomatoid drug eruption.
  • The pathomechanisms of both types of drug eruption, i.e. baboon syndrome and lymphomatoid drug eruption, are not fully understood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cisplatin / adverse effects. Deoxycytidine / analogs & derivatives. Intertrigo / chemically induced
  • [MeSH-minor] Aged. Humans. Lung Neoplasms / drug therapy. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The International Society of Dermatology.
  • (PMID = 20883412.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Willemze R, Meijer CJ: Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am; 2003 Dec;17(6):1319-32, vii-viii
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary cutaneous CD30-positive (anaplastic) large T-cell lymphoma and lymphomatoid papulosis have many overlapping clinical, histologic, and immunophenotypic features.
  • We provide the clinician with practical guidelines for the diagnosis, management, and treatment of patients within this spectrum of primary cutaneous CD30-positive lymphoproliferative disorders.
  • Most patients within this spectrum of disease have an excellent prognosis.
  • Multi-agent chemotherapy should be reserved for patients who have extracutaneous disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Lymphomatoid Papulosis / etiology. Lymphomatoid Papulosis / pathology. Male. Middle Aged. Remission, Spontaneous. Virus Diseases / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14710887.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


36. Au WY, Yeung CK, Chan HH, Wong RW, Shek TW: CD30-positive cutaneous T-cell lymphoma with concurrent solid tumour. Br J Dermatol; 2002 Jun;146(6):1091-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis of CD30+ cutaneous T-cell lymphoma (CTCL) is good in the absence of nodal primary or disseminated disease.
  • These lesions can undergo spontaneous regression, and overlap with the group of lesions of lymphomatoid papulosis.
  • The CTCL responded completely to chemotherapy in one patient, who eventually succumbed to gastric cancer.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12072086.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, Neoplasm
  •  go-up   go-down


37. Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood; 2000 Dec 1;96(12):3681-95
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ALK(+) ALCL predominantly affects young male patients and, if treated with chemotherapy, has a favorable prognosis.
  • It shows a broad morphologic spectrum, with the "common type," the small cell variant, and the lymphohistiocytic variant being most commonly observed.
  • The knowledge of the existence of these variants is essential in establishing a correct diagnosis.
  • The morphology and the immunophenotype of primary cutaneous ALCL show an overlap with that of lymphomatoid papulosis.
  • In contrast, large B-cell lymphomas with anaplastic morphology are believed to represent not a separate entity but a morphologic variant of diffuse large B-cell lymphoma.
  • Malignant lymphomas with morphologic features of both Hodgkin disease and ALCL have formerly been classified as Hodgkin-like ALCL.
  • Recent immunohistologic studies, however, suggest that ALCLs Hodgkin-like represent either cases of tumor cell-rich classic Hodgkin disease or (less commonly) ALK(+) ALCL or ALK(-) ALCL. (Blood.
  • [MeSH-minor] Gene Rearrangement. Hodgkin Disease. Humans. Immunophenotyping. Nuclear Proteins / genetics. Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11090048.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 157
  •  go-up   go-down


38. Ingen-Housz-Oro S, Bagot M: [Cutaneous lymphomas]. Rev Prat; 2009 Nov 20;59(9):1207-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous lymphomas are lymphoproliferations affecting skin only at the time of diagnosis.
  • There are two major types, B-cell lymphomas and T-cell lymphomas, which prognosis depends of histological subtype and staging evaluation.
  • In cutaneous B-cell lymphomas, there are two indolent subtypes (primary cutaneous marginal zone B-cell lymphoma and primary cutaneous follicle center lymphoma) and one more aggressive type (primary cutaneous diffuse large B-cell lymphoma, leg type).
  • Classification of T-cell lymphomas distinguishes indolent subtypes such as mycosis fungoides, the most frequent of T-cell lymphomas, and CD30+ lymphoproliferations such as lymphomatoid papulosis, whereas other T-cell lymphoma subtypes have a more pejorative prognosis such as Sezary syndrome (erythrodermic and leukemic form of mycosis fungoides) and CD30- lymphomas.
  • Staging evaluation with CT-scan of chest, abdomen and pelvis, bone marrow examination if necessary and lymph node biopsy if palpable node over 1 or 1.5 cm diameter, is necessary for therapeutic decision.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / surgery. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiography. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Mycosis Fungoides / diagnosis. Mycosis Fungoides / radiography. Neoplasm Staging. Prognosis. Radiography, Abdominal. Radiography, Thoracic. Sezary Syndrome / diagnosis. Sezary Syndrome / pathology. Sezary Syndrome / radiography. Skin / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961071.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 16
  •  go-up   go-down


39. Foss HD, Marafioti T, Stein H: [The many faces of anaplastic large cell lymphoma]. Pathologe; 2000 Mar;21(2):124-36
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Die vielen Gesichter des anaplastischen grosszelligen Lymphoms.
  • ALK-positive ALC-lymphoma predominantly affects young male patients and if treated with chemotherapy has a favourable prognosis.
  • They show a broad morphological spectrum, with the "common type", the small cell variant and the lymphohistiocytic variant being most commonly observed.
  • The knowledge of the existence of these variants is essential in establishing the correct diagnosis.
  • The morphology and the immuno-phenotype of primary cutaneous ALC-lymphoma shows an overlap with that of lymphomatoid papulosis.
  • In contrast, large B-cell-lymphomas with anaplastic morphology are now believed not to represent an own entity but a morphologic variant of diffuse large B-cell lymphoma.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840818.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 32
  •  go-up   go-down


40. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL: Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther; 2005;7(3):R666-76
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
  • Various dermatological conditions have been reported during tumor necrosis factor (TNF)-alpha-blocking therapy, but until now no prospective studies have been focused on this aspect.
  • The present study was set up to investigate the number and nature of clinically important dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis (RA).
  • RA patients starting on TNF-alpha-blocking therapy were prospectively followed up.
  • The patients with a dermatological event were compared with a group of prospectively followed up RA control patients, naive to TNF-alpha-blocking therapy and matched for follow-up period.
  • 289 RA patients started TNF-alpha-blocking therapy.
  • TNF-alpha-blocking therapy was stopped in 19 (26%) of these 72 patients because of the dermatological event.
  • More of the RA patients given TNF-alpha-blocking therapy (25%) than of the anti-TNF-alpha-naive patients (13%) visited a dermatologist during follow-up (P < 0.0005).
  • Events were recorded more often during active treatment (0.16 events per patient-year) than during the period of withdrawal of TNF-alpha-blocking therapy (0.09 events per patient-year, P < 0.0005).
  • The events recorded most frequently were skin infections (n = 33), eczema (n = 20), and drug-related eruptions (n = 15).
  • Other events with a possible relation to TNF-alpha-blocking therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid-papulosis-like eruption.
  • This study is the first large prospective study focusing on dermatological conditions during TNF-alpha-blocking therapy.
  • It shows that dermatological conditions are a significant and clinically important problem in RA patients receiving TNF-alpha-blocking therapy.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Skin Diseases / chemically induced. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Dec 4;354(9194):1932-9 [10622295.001]
  • [Cites] J Rheumatol. 1998 Oct;25(10):1900-7 [9779842.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):478-86 [10075615.001]
  • [Cites] Ann Intern Med. 1999 Oct 19;131(8):634 [10523238.001]
  • [Cites] Ann Rheum Dis. 2004 Dec;63(12):1538-43 [15242866.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):243-9 [10693862.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):385-90 [10972371.001]
  • [Cites] Rheumatology (Oxford). 2000 Sep;39(9):1020-6 [10986309.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1594-602 [11096166.001]
  • [Cites] Mayo Clin Proc. 2001 Jun;76(6):653-6 [11393506.001]
  • [Cites] Lancet. 2001 Jun 9;357(9271):1842-7 [11410193.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1098-104 [11596589.001]
  • [Cites] Rheumatology (Oxford). 2001 Nov;40(11):1317-9 [11709621.001]
  • [Cites] J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6 [11756941.001]
  • [Cites] Rheumatology (Oxford). 2002 Jan;41(1):116-7 [11792895.001]
  • [Cites] Postgrad Med J. 2002 Jan;78(915):47-8 [11796874.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):579-80 [11867114.001]
  • [Cites] Br J Dermatol. 2002 Feb;146(2):334-5 [11903255.001]
  • [Cites] Lancet. 2002 Apr 6;359(9313):1187-93 [11955536.001]
  • [Cites] Ann Rheum Dis. 2002 Sep;61(9):793-8 [12176803.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2257-8; author reply 2259 [12209539.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1258-9 [12225003.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2287-93 [12355475.001]
  • [Cites] Ann Rheum Dis. 2002 Nov;61(11):968-74 [12379517.001]
  • [Cites] Lupus. 2002;11(11):753-5 [12475006.001]
  • [Cites] Arthritis Rheum. 2003 Jan;48(1):35-45 [12528101.001]
  • [Cites] Arthritis Rheum. 2003 Jan;48(1):218-26 [12528122.001]
  • [Cites] Rheumatol Int. 2003 Jan;23(1):37-40 [12548440.001]
  • [Cites] Rheum Dis Clin North Am. 2003 Feb;29(1):185-202 [12635507.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):1165-6; author reply 1166 [12687569.001]
  • [Cites] Arthritis Rheum. 2003 Jun;48(6):1667-75 [12794835.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1):160-1 [12833036.001]
  • [Cites] Arthritis Rheum. 2003 Jul;48(7):1853-7 [12847679.001]
  • [Cites] Clin Exp Rheumatol. 2003 Jul-Aug;21(4):481-4 [12942701.001]
  • [Cites] J Rheumatol. 2003 Oct;30(10):2287-91 [14528531.001]
  • [Cites] Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3 [14532145.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3013-22 [14613261.001]
  • [Cites] APMIS. 2003 Oct;111(10):940-4 [14616545.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632 [14676082.001]
  • [Cites] Ann Pharmacother. 2004 Jan;38(1):54-7 [14742794.001]
  • [Cites] J Rheumatol Suppl. 2004 Mar;69:14-21 [15053447.001]
  • [Cites] Arthritis Rheum. 2004 May;50(5):1400-11 [15146409.001]
  • [Cites] J Rheumatol. 2004 Oct;31(10):1912-7 [15468353.001]
  • [Cites] Int J Dermatol. 1982 Dec;21(10):563-72 [6761281.001]
  • [Cites] J Am Acad Dermatol. 1983 Apr;8(4):439-57 [6343438.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Br J Rheumatol. 1993 Sep;32(9):798-803 [8103699.001]
  • [Cites] Ann Rheum Dis. 1994 Apr;53(4):224-8 [8203949.001]
  • [Cites] Arthritis Rheum. 1995 Jan;38(1):44-8 [7818570.001]
  • [Cites] J Dermatol. 1995 May;22(5):324-9 [7673550.001]
  • [Cites] J Rheumatol. 2003 Apr;30(4):680-90 [12672184.001]
  • (PMID = 15899052.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC1174960
  •  go-up   go-down


41. Dukic R, Derragui A, Geiss S, Wilhelm JM, Thannberger P, Colson A, Kieffer P: [Minocycline-induced lymphomatoid papulosis]. Rev Med Interne; 2004 May;25(5):401-4
Hazardous Substances Data Bank. MINOCYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minocycline-induced lymphomatoid papulosis].
  • [Transliterated title] Papulose lymphomatoïde atypique à grandes cellules supposée déclenchée par la minocycline.

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15110963.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; FYY3R43WGO / Minocycline
  •  go-up   go-down


42. Seifert G, Tautz C, Seeger K, Henze G, Laengler A: Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis. J Eur Acad Dermatol Venereol; 2007 Apr;21(4):558-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphomatoid Papulosis / drug therapy. Phytotherapy / methods. Plant Extracts / therapeutic use. Skin Neoplasms / drug therapy. Viscum
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Follow-Up Studies. Humans. Injections, Intralesional. Injections, Subcutaneous. Male. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374000.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / viscum fraxini-2
  •  go-up   go-down


43. Spires N, McGibbon D: Lymphomatoid papulosis improving on hormone-replacement therapy. Clin Exp Dermatol; 2009 Jul;34(5):635-6
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis improving on hormone-replacement therapy.
  • [MeSH-major] Estrogen Replacement Therapy. Lymphomatoid Papulosis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236413.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


44. Leo AM, Ermolovich T: Lymphomatoid papulosis while on efalizumab. J Am Acad Dermatol; 2009 Sep;61(3):540-1
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis while on efalizumab.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Drug Eruptions / pathology. Immunosuppressive Agents / adverse effects. Lymphomatoid Papulosis / chemically induced. Lymphomatoid Papulosis / pathology. Psoriasis / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700027.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunosuppressive Agents; 0 / efalizumab
  •  go-up   go-down


45. Hoetzenecker W, Guenova E, Hoetzenecker K, Yazdi A, Röcken M, Berneburg M: Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. Eur J Dermatol; 2009 Nov-Dec;19(6):646-7
Genetic Alliance. consumer health - Lymphomatoid papulosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy.
  • [MeSH-major] Lymphomatoid Papulosis / drug therapy. Lymphomatoid Papulosis / pathology. PUVA Therapy
  • [MeSH-minor] Child. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797036.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


46. Outlaw W, Fleischer A, Bloomfeld R: Lymphomatoid papulosis in a patient with Crohn's disease treated with infliximab. Inflamm Bowel Dis; 2009 Jul;15(7):965-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid papulosis in a patient with Crohn's disease treated with infliximab.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Antibodies, Monoclonal / administration & dosage. Crohn Disease / complications. Crohn Disease / drug therapy. Lymphomatoid Papulosis / complications. Skin Neoplasms / complications


47. Hughes PS: Treatment of lymphomatoid papulosis with imiquimod 5% cream. J Am Acad Dermatol; 2006 Mar;54(3):546-7
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lymphomatoid papulosis with imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / administration & dosage. Interferon Inducers / administration & dosage. Lymphomatoid Papulosis / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16488317.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dosage Forms; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


48. Fujimi A, Kanisawa Y, Kikuchi S, Okuda T, Sato Y, Doi T, Ohta H, Umeda I, Nobuoka A: [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib]. Nihon Naika Gakkai Zasshi; 2007 Dec 10;96(12):2794-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
  • [MeSH-major] Hypereosinophilic Syndrome / drug therapy. Oncogene Proteins, Fusion / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / genetics. T-Lymphocytes / pathology. mRNA Cleavage and Polyadenylation Factors / genetics

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203417.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


49. Koury MJ, Newman JH, Murray JJ: Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med; 2003 Nov;115(7):587-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hypereosinophilic Syndrome / drug therapy. Lymphomatoid Papulosis / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Benzamides. Drug Therapy, Combination. Female. Humans. Imatinib Mesylate. Interleukin-5 / blood. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Hypereosinophilic syndromes.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599646.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Benzamides; 0 / Interleukin-5; 0 / Piperazines; 0 / Pyrimidines; 0 / mepolizumab; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


50. Kontos AP, Kerr HA, Malick F, Fivenson DP, Lim HW, Wong HK: 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoimmunol Photomed; 2006 Jun;22(3):168-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides.
  • [MeSH-major] Lymphomatoid Papulosis / radiotherapy. Mycosis Fungoides / drug therapy. PUVA Therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719874.001).
  • [ISSN] 0905-4383
  • [Journal-full-title] Photodermatology, photoimmunology & photomedicine
  • [ISO-abbreviation] Photodermatol Photoimmunol Photomed
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


51. Afridi S, Bacon CM, Bowling J, Goadsby PJ: Verapamil and lymphomatoid papulosis in chronic cluster headache. J Neurol; 2004 Apr;251(4):473-5
Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verapamil and lymphomatoid papulosis in chronic cluster headache.
  • [MeSH-major] Cluster Headache / drug therapy. Lymphomatoid Papulosis / chemically induced. Verapamil / adverse effects
  • [MeSH-minor] Aged. Chronic Disease. Humans. Male

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Genetic Alliance. consumer health - Cluster headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15083295.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] CJ0O37KU29 / Verapamil
  •  go-up   go-down






Advertisement